Oral acyclovir for the prevention of herpes-associated erythema multiforme

Lemak, Margaret A.; Duvic, Madeleine; Bean, Samuel F.

doi:10.1016/s0190-9622(86)70141-2

Cited by 75 publications

(18 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[187][188][189][190][191] Recurrent EM refers to an infrequent variant of this disease characterized by multiple outbreaks of EM often associated with herpes reactivation. 11,72,124,187,[191][192][193][194][195][196][197][198][199] Asymptomatic viral shedding in the absence of clinical herpes may also precipitate herpes-associated erythema multiforme (HAEM). 188,193,200 Using PCR, presence of viral DNA in HAEM lesions have been demonstrated.…”

Section: Diagnosismentioning

confidence: 99%

Human herpes simplex virus infections: Epidemiology, pathogenesis, symptomatology, diagnosis, and management

Fatahzadeh¹,

Schwartz²

2007

Journal of the American Academy of Dermatology

446

431

View full text Add to dashboard Cite

Section: Diagnosismentioning

confidence: 99%

Human herpes simplex virus infections: Epidemiology, pathogenesis, symptomatology, diagnosis, and management

Fatahzadeh¹,

Schwartz²

2007

Journal of the American Academy of Dermatology

446

431

View full text Add to dashboard Cite

“…An estimated 50 to 80% of cases of recurrent erythema multiforme are HSV-associated (109). A causal role for recurrent HSV infection has been strongly suggested by the clinical improvement that occurs when suppressive doses of nucleoside antivirals are given (147). The pathogenesis is controversial.…”

Section: Potential Toxicities Of Vaccinesmentioning

confidence: 99%

Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research

2003

View full text Add to dashboard Cite

Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) cause prevalent, chronic infections that have serious outcomes in some individuals. Neonatal herpes may occur when the infant traverses the cervix during maternal genital herpes. Genital herpes is a major risk factor for human immunodeficiency virus type 1 transmission. Considerable efforts have been made to design and test vaccines for HSV, focusing on genital infection with HSV-2. Several protein subunit vaccines based on HSV-2 envelope glycoproteins have reached advanced-phase clinical trials. These antigens were chosen because they are the targets of neutralizing-antibody responses and because they elicit cellular immunity. Encouraging results have been reported in studies of treatment of HSV-seronegative women with a vaccine consisting of truncated glycoprotein D of HSV-2 and a novel adjuvant. Because most sexual HSV transmission occurs during asymptomatic shedding, it is important to evaluate the impact of vaccination on HSV-2 infection, clinically apparent genital herpes, and HSV shedding among vaccine recipients who acquire infection. There are several other attractive formats, including subunit vaccines that target cellular immune responses, live attenuated virus strains, and mutant strains that undergo incomplete lytic replication. HSV vaccines have also been evaluated for the immunotherapy of established HSV infection

show abstract

“…It is actually considered as a reaction pattern to many different stimuli 1 . The commonest association is with a preceding herpes simplex infection 2,3 . Other important provocative factors comprise drug sensitivities, mycoplasma and bacterial infections, and autoimmune diseases 1–5 .…”

Section: Introductionmentioning

confidence: 99%

“…The commonest association is with a preceding herpes simplex infection 2,3 . Other important provocative factors comprise drug sensitivities, mycoplasma and bacterial infections, and autoimmune diseases 1–5 . Pathogen microorganisms cannot be found in the skin lesions and a delayed immunological hypersensitivity mechanism should be involved.…”

Section: Introductionmentioning

confidence: 99%